I wouldn't disagree that if they and IMUC either waited longer to capture the data beyond the median or were more selective genetically with their patient populations, they may have had better results. You can't pick a very specific target and have less specific population. I also like multiple targets because 1 target could be down regulated. Epitope spread can occur ala provenge but I would rather arm the immune system with as much information as we possibly can specific to the patient. AF wrongly calls this birdshot vs rifle shot. Saying that bird shot will not break the skin of a Rhino. Make no mistake, this is not bird shot but multiple snipers all going after the same Rhino. 1 is aiming at the head, 1 at the lungs, 1 at the heart, 1 at the spine. But I will agree that letting it play out a little longer beyond the 50% median may have shown an improvement. That is the problem with previous cancer trials. They are looking for a 1 size fits all treatment in a population that is not 1 size fits all. Newer trials are narrowing the scope and the nature of DC vax theoretically gets around this because it is tailored to the patient.
News 
Market Data 
Discover 
